Notícias e Atividades da SV Health Investors

SV Health Investors tem presença direta em 2 países.

Veja o organograma con seus 66 executivos principais

Biografias mais buscadas da SV Health Investors

• Eugene Hill, Chairman of the Board
• Paul LaViolette, Managing Partner, Medical Technology and Chief Op...
• Greg Madden, Managing Partner, Medtech and Healthcare Growth

Recentes movimentos de executivos em SV Health Investors

• Miles Gerson, ingressou na Companhia como Partner, Therapeutics  (Notícia publicada em 24 de março de 2026).

Criar um alerta
para seguir os movimentos de executivos da SV Health Investors.

SV Health Investors possui 1.643 concorrentes concorrentes Griffin Gaming Partners (Estados Unidos), BlackRock (Estados Unidos) e KKR (Estados Unidos).

Popular M&A news in Fundo

• Bridgepoint has announced the acquisition of Obagi Medical Products  (publicado em 4 de junho de 2026).
• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (publicado em 3 de junho de 2026).
• Prime Capital Financial adquiriu Access Capital Partners (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Fundo

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer da Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director da Vanguard
• Hemant Taneja - Chief Executive Officer and Managing Director da General Catalyst Partners

Saiba mais sobre a indústria do Fundo

Últimos comunicados de imprensa de SV Health Investors

• Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial - SV Health Investors
• Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer - SV Health Investors
• Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research - SV Health Investors
• AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid - SV Health Investors
• AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial - SV Health Investors
• Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update - SV Health Investors
• News - SV Health Investors
• SV Health Investors Acquires EpiVax - SV Health Investors
• Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS - SV Health Investors
• Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic - SV Health Investors
• View more press releases Close

Redes sociais sobre SV Health Investors

• SV Health Investors na Wikipedia, Google News e Yahoo Finance
• SV Health Investors na LinkedIn, X (Twitter) e YouTube